spacer
home > ict > winter 2017 > editor’s comment
PUBLICATIONS
International Clinical Trials

Editor’s Comment

In this edition, we highlight several aspects of patient recruitment and retention. Getting patients to participate in clinical trials is an ongoing challenge throughout the pharmaceutical industry. Stewart Rosen and Nicola J Smith at QuintilesIMS discusses how the human touch can alleviate some problems in subject recruitment. He notes that nearly two million patients take part in 80,000 companysponsored trials every year. However, as Ken Getz – founder of the Center for Information and Study on Clinical Research Participation – comments, companies are increasingly struggling to attract and retain the requisite number of participants to complete studies on time and within budget. It is estimated that almost half of all sites miss their enrolment targets. One solution proposed by Rosen and Smith is that nurses and other healthcare providers can play a crucial role as educators in the recruitment process; they feel that the function of these educators will expand as the number of clinical trials continues to rise.

Bruno Gagnon and Nick Payton at Comprehend discuss how patient centricity is a growing trend in the pharma sector and how this can result in patients being treated as consumers, rather than subjects.They describe how the three steps: leakage diagnosis, root causes of withdrawal and closing the loop, can help to retain patients by means of a proactive education of participants, which empowers them to make more informed decisions. The role of clinical operations is vital in this regard. Research nurses in particular – with respect to long-term medical conditions in clinical trials – are discussed by Julie Millar, Gaynor Mates and Louise Doyle at CK Aspire. They believe that studies carried out in ‘real world conditions’ can be complementary to traditional randomised clinical trials, and explore how research nurses must adapt to the varying examination methodologies when recruiting patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement